BioSpace News Archive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) will host a global webcast on Tuesday 2 June 2020 at 7.30am, Australia Eastern Standard Time (AEST) / Monday 1 June 2020 at 5.30pm, Eastern Daylight Time (EDT).

Fortress Biotech, Inc., an innovative biopharmaceutical company, announced that it has priced an underwritten public offering of 555,556 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $18.00 per share, with expected gross proceeds to Fortress of approximately $10 million.

Today, the U.S. Food and Drug Administration approved artesunate for injection to treat severe malaria in adult and pediatric patients. Treatment of severe malaria with intravenous (IV) artesunate should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.

Los Angeles Surgeon Gabriel Goren, MD says ‘Rejuvahands TM’ is the ONLY enduring option for seniority associated unsightly looking bulging hand vein

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of methods used to evaluate the on-target efficiency and precision of Homology’s in vivo phenylketonuria (PKU) gene editing program.

The Institute of Cancer Research, London, has strongly welcomed the approval by the US Food and Drug Administration (FDA) of the genetically targeted drug olaparib for some men with advanced prostate cancer.

Pharmaceutical entrepreneur and University of the Pacific alumna Dr. Jie Du has donated $5 million to found the Jie Du Center for Innovation and Excellence for Drug Development at the university’s Thomas J. Long School of Pharmacy in Stockton.

Abivax SA (Euronext Paris: FR0012333284 – ABVX), a late stage clinical biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today that the German regulatory authority for drugs and medical products, BfArM (Bundesinstitut für Arnzeimittel und Medizinprodukte), has approved its Phase 2b/3 study of ABX464 in COVID-19 patients.

The shareholders of Selvita S.A. [WSE:SLV] - one of the largest preclinical contract research organizations in Europe, have made a decision to go ahead with the issue of no more than 2.38 million C series shares, which constitutes about 15 percent of the current Company’s share capital.

Neovasc Inc. announced an offering of convertible notes and warrants to Strul Medical Group for gross proceeds of up to US$5.0 Million;